New Age Alpha Advisors LLC Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

New Age Alpha Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,482 shares of the specialty pharmaceutical company’s stock, valued at approximately $183,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its stake in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after buying an additional 115,102 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the last quarter. GW&K Investment Management LLC lifted its position in Jazz Pharmaceuticals by 26.6% during the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after buying an additional 97,589 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Jazz Pharmaceuticals by 501.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock worth $13,800,000 after buying an additional 93,422 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $11,373,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,236 shares of company stock worth $3,837,680 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on JAZZ shares. Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $145.00 to $179.00 in a report on Friday, March 7th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Royal Bank of Canada decreased their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $126.44 on Thursday. The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 1.04 and a beta of 0.44. The firm’s fifty day simple moving average is $132.54 and its 200-day simple moving average is $122.92. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.